This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Trending Stock Cigna Corporation (CI) a Buy Now?
by Zacks Equity Research
Cigna (CI) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Cigna (CI) & Oscar Health Boost Presence in Philadelphia
by Zacks Equity Research
Cigna (CI) & Oscar Health's plans are likely to target businesses with 1-50 employees.
Is Cigna (CI) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana (HUM) Closes $2.8B Kindred Hospice Divestment to CD&R
by Zacks Equity Research
Humana (HUM) retaining the remaining 40% stake will likely enable it to gain from the standalone company's long-term success.
Cigna Corporation (CI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Finance Stocks Lagging Cigna (CI) This Year?
by Zacks Equity Research
Here is how Cigna (CI) and Ashford (AINC) have performed compared to their sector so far this year.
Is Most-Watched Stock Cigna Corporation (CI) Worth Betting on Now?
by Zacks Equity Research
Cigna (CI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Company News for Aug 5, 2022
by Zacks Equity Research
Companies in The News Are: COIN, BLK, META, LLY, CI
Cigna (CI) Q2 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Cigna's (CI) second-quarter results indicate solid membership growth plus sound contributions from Evernorth and Cigna Healthcare segments. An upped 2022 EPS outlook remains noteworthy.
Initial Jobless Claims Rise, BOE Launches Biggest Rate Hike
by Zacks Equity Research
Stock futures point to a flat opening today as Weekly Jobless Claims data displayed an increase.
Initial Jobless Claims Come in Higher
by Zacks Equity Research
Initial Jobless Claims Come in Higher
Cigna (CI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 14.34% and 2.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) to Announce Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Cigna's (CI) second-quarter results are likely to reflect higher pharmacy revenues and a growing customer base.
Cigna (CI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Cigna (CI) closed at $274.83 in the latest trading session, marking a +0.81% move from the prior day.
The Zacks Analyst Blog Highlights Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina
by Zacks Equity Research
Johnson & Johnson, Cigna, Vertex Pharmaceuticals, Xcel Energy and Illumina have been included in this Analyst Blog.
Top Analyst Reports for Johnson & Johnson, Cigna, & Vertex
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Cigna Corporation (CI), and Vertex Pharmaceuticals Incorporated (VRTX).
Should Invesco S&P 500 Pure Value ETF (RPV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RPV
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M
by Zacks Equity Research
Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.
Should You Retain Chubb Limited (CB) Stock in Your Portfolio?
by Zacks Equity Research
Chubb Limited (CB) is well poised for growth on the back of rate increases, increased dividends on public equities, strategic acquisitions and effective capital deployment.
Is Invesco S&P 500 Pure Value ETF (RPV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RPV
3 Large-Cap Stocks up More Than 20% Year-To-Date
by Derek Lewis
All three sport strong Zacks Ranks - a significant perk that instills confidence in these companies' share performances moving forward.
Why Cigna (CI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cigna Corporation (CI) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should Value Investors Buy Cigna (CI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cedar Realty Trust (CDR) Outperforming Other Finance Stocks This Year?
by Zacks Equity Research
Here is how Cedar Realty Trust (CDR) and Cigna (CI) have performed compared to their sector so far this year.